Search

Displaying results 1071 - 1080 of 10000 in total
  1. Drug

    Pantoprazole

    go.drugbank.com/drugs/DB00213
    ApprovedInvestigational

    Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme … increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.

    Products: PANTOPRAZOLO EG, PANTO 40 MG IV ENJ. LIYOFILIZE TOZ ICEREN FLAKON
  2. Drug

    Terpin hydrate

    go.drugbank.com/drugs/DB13163
    ApprovedWithdrawn

    Elixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies. … It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate

  3. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    It is thought to reduce symptoms through its actions on histamine receptors. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.

    Synonyms: N-methyl-2-pyridineethanamine, N-methyl-2-(2-pyridinyl)ethanamineProducts: BETAISTINA EG, BETAVERT N 8MG
  4. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors … [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression

    Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine
  5. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression … across metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies.

  6. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma … Attention Deficit Hyperactivity Disorder (ADHD) is an early-onset neurodevelopmental disorder that often extends into adulthood and is characterized by developmentally inappropriate and impaired attention

  7. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected … by an FDA-approved test [L2939].

  8. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection … It was approved by the FDA after being given the status of priority review for on July 7, 2015.

    Mixtures: ENTRESTO FILM COATED TABLET 100MG, Uperio 100mg Film-coated Tablets
  9. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. … [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

    Synonyms: 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrileMixtures: COMPLERA FILM-COATED TABLET 200MG/25MG/300MG, Odefsey® (200mg Emtricitabine/25mg Rilpivirine/25mg Tenofovir alafenamide) film coated tablets
  10. Drug

    Cefaclor

    go.drugbank.com/drugs/DB00833
    ApprovedInvestigational

    Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.

    Products: CEFACLOR EG, PANORAL 500MG